Centessa Board Member Receives Major Stock Incentive Package Worth Potential Millions

Rhea-AI Filing Summary

Centessa Pharmaceuticals director Carol Stuckley received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 40,000 share options to purchase ordinary shares
• Exercise price set at $12.43 per share
• Options expire on June 20, 2035
• Vesting occurs at earlier of:
  • First anniversary of grant date
  • Next annual shareholder meeting

The options are subject to continued service as director through the vesting date. Each ordinary share may be represented by one American Depositary Share (ADS). The transaction was reported via Form 4 filing with attorney-in-fact signature dated June 24, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stuckley Carol

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	40,000	$0.00	--

Holdings After Transaction: Share Option (right to buy) — 40,000 shares (Direct)

Footnotes (1)

1. The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuckley Carol

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FLOOR, 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE X0 WA14 2DT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$12.43	06/20/2025		A		40,000		(1)	06/20/2035	Ordinary Shares(2)	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

	/s/ Iqbal Hussain, attorney-in-fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Carol Stuckley receive from CNTA on June 20, 2025?

Carol Stuckley received 40,000 share options (right to buy) from Centessa Pharmaceuticals plc (CNTA) on June 20, 2025, with an exercise price of $12.43 per share.

What is the vesting schedule for CNTA director Carol Stuckley's stock options granted in June 2025?

The stock options will vest in full on either (i) the first anniversary of the grant date (June 20, 2026) or (ii) CNTA's next annual meeting of shareholders, whichever comes first, subject to continued service as a director.

When do Carol Stuckley's CNTA stock options expire?

The stock options granted to Carol Stuckley expire on June 20, 2035, which is 10 years from the grant date.

What is Carol Stuckley's role at CNTA according to the Form 4 filing?

According to the Form 4 filing, Carol Stuckley serves as a Director of Centessa Pharmaceuticals plc (CNTA), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the exercise price of CNTA stock options granted to Carol Stuckley in June 2025?

The exercise price of the stock options granted to Carol Stuckley is $12.43 per share.